Protagenic Therapeutics Inc (PTIX) USD0.0001

Sell:$0.25Buy:$0.27$0.05 (28.14%)

Prices delayed by at least 15 minutes
Sell:$0.25
Buy:$0.27
Change:$0.05 (28.14%)
Prices delayed by at least 15 minutes
Sell:$0.25
Buy:$0.27
Change:$0.05 (28.14%)
Prices delayed by at least 15 minutes

Company Information

About this company

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Key people

Garo H. Armen
Executive Chairman of the Board
Alexander K. Arrow
Chief Financial Officer
Andrew Slee
Chief Operating Officer
Robert Burton Stein
Director, Chief Medical Officer
Khalil Z. Barrage
Independent Director
Jennifer S. Buell
Independent Director
Brian J. Corvese
Independent Director
Timothy R. Wright
Independent Director
Click to see more

Key facts

  • EPIC
    PTIX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US74365N2027
  • Market cap
    $1.41m
  • Employees
    1
  • Shares in issue
    7.53m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.